Special Issues

Special Issue Title: Surgery for Gynecological Cancer: Current Evidences and Perspectives

· Print Special Issue Flyer

· Deadline for manuscript submissions: 30 September 2021

Special Issue Editor

Guest Editor

Dr. Federico Ferrari

Department of Obstetrics & Gynecology and Neonatology of ASST Spedali Civili (Tertiary Teaching Hospital in Brescia), Italy

Interests: Gynecologic Oncology

Special Issue Information

Dear Colleagues,

Gynecological surgery is the oldest therapeutic approach for the treatment of malignancy of the female tract. Surgical techniques evolved dramatically in the last decades, according to the improvement and implementation of technology and perioperative assistance. Appropriateness of surgery and standardization of the procedures are an ongoing debate and a paradigmatic example is the surprising finding regarding the worst prognosis of minimally invasive approach in cervical cancer. In fact, many international studies are reporting different strategies and study hypothesis to overcome this issue. On the other side minimally invasive surgery and the tailoring of surgical lymph nodal staging play a big role in endometrial and vulvar cancer, representing a paradigm of shifting towards less invasive, but appropriate procedures. Aggressive open surgery remains on the contrary, a cornerstone for advanced ovarian cancer, even though pioneers reported experiences with minimally invasive surgery in selected patients. Nonetheless, there are many rarer gynecological cancers requiring a stronger evidence based knowledge about their surgical approach, especially in the conservative surgical approach. Finally, a common framework of perioperative care in gynecological surgery is mandatory and nowadays, enhanced recovery after surgery protocol should be the new standard of care.

The aim of this special issue is to highlight the evolution of surgical indications, procedures and perioperative care for the treatment of gynecological cancers, with an overview of the current trends and future perspectives.

Dr. Federico Ferrari

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. Submitted papers should be well formatted and use good English.

Surgery; Gynecological Cancer; Surgical Indications; Perioperative Care

Share This Special Issue


Planned Papers

Type: Review

Title:  Aggressive surgery for advanced ovarian cancer: an update on current trend
Author: Dr. Sara forte

Type: Original Research

Title: Impact of low serum albumin level and concomitant bowel resection in optimally debulked ovarian cancer: a multicentric retrospective analyses
Author: Dr. Federico Ferrari

Type: Original Research

Title: Clinicopathological Risk Factors and Survival Analysis of Patients with Synchronous Ovarian and Endometrial Cancer
Author: Mehmet Sait Bakır

Please wait a minute...
For Selected: Toggle Thumbnails
Clinicopathological risk factors and survival analysis of ovarian cancer with synchronous endometrial cancer diagnosed after surgery
Mehmet Sait Bakır, Özer Birge, Ceyda Karadag, Selen Doğan, Hasan Aykut Tuncer, Tayup Simsek
European Journal of Gynaecological Oncology    2021, 42 (3): 499-505.   DOI: 10.31083/j.ejgo.2021.03.2336
Abstract107)   HTML5)    PDF(pc) (195KB)(140)       Save

Objective: In the present study, we tried to retrospectively evaluate the clinicopathological characteristics, prognosis and survival of patients with synchronous ovarian and endometrial cancer (SOEC). Material and methods: The data of patients with ovarian cancer who had been admitted to our hospital between February 2006 and March 2019 were retrospectively obtained from the hospital's electronic archive system collected after having obtained the ethics committee approval. Thirty-six patients with epithelial ovarian cancer and simultaneously diagnosed with primary endometrial cancer were included in the study. Patients with non-epithelial ovarian cancer, recurrent, metastatic and metachronous tumor, borderline ovarian tumor, uterine sarcoma and carcinosarcoma, and patients who had not attended regular controls were excluded from the study. Progression-free survival (PFS) and overall survival (OS) were compared using the Kaplan Meier survival analysis. The log rank test was used to test the effect of subgroups on survival. Results: The mean age of the SOEC patients included in the study was 52.05 ± 13.46 years. Of the patients, 8.3% had endometriosis and 16.7% had concurrent adenomyosis. Optimal surgery was seen to have been performed when evaluated with regard to post-operative residual tumor (R0, R1 and R2 61.1%, 33.3% and 5.6%, respectively). The histological grade was Grade 3 in most of the patients (44.4%). When the histology of SOEC patients was examined, endometrioid type was seen to be the most frequent in 18 patients (50%), followed by the serous type in 10 patients (27.8%). The least frequent was clear histology in 2 patients (5.6%). On the other hand, with regard to the endometrial cancer histology of SOEC patients, while the most common type was endometrioid type with 27 patients (75%), serous histological type was seen in 8 patients (22.2%). The five-year progression-free survival (PFS) was 43.6% for all patients, while the overall survival (OS) was 67.1%. The median PFS was 32 months, while the median OS was 89.6 months. In the subgroup analysis was performed as serous/serous histological type with SOEC patients with endometrioid/endometrioid, the median PFS was 53.8 months for the endometrioid/endometrioid type and 11.5 months for the serous/serous type, and it was statistically significant (p: 0.001). In terms of OS for both groups, it was 110.2 and 36.8 months, respectively, and it was statistically significant (p: 0.001). Conclusion: Endometrioid type endometrial cancer is more common than serous in synchronous ovarian and endometrial cancer patients and serous type has a worse prognosis than endometrioid.
Related Articles | Metrics

Current Issue

  • Volume 42, Issue 5